RHIZEN-PHARMACEUTICALS
2.12.2020 10:35:17 CET | Business Wire | Press release
Rhizen Pharmaceuticals, a clinical-stage oncology-focussed biopharmaceutical company, today announced the approval of its Investigational New Drug (IND) application by the U.S. Food and Drug Administration (FDA) to study its oral DHODH inhibitor for SARS-CoV-2 infection. The company announced that initial study shall evaluate single ascending doses of RP7214 in healthy volunteers and that dosing is expected to commence in early December 2020. The company also announces positive feedback from the FDA during its pre-IND discussion on its plans to follow-up this study with a multiple-ascending dose study in Covid-19 patients.
Dihydroorotate dehydrogenase (DHOHD) is a key enzyme involved in pyrimidine biosynthesis in the cell. RP7214 is potentially a best-in-class selective DHODH inhibitor that has shown potent inhibition of Covid-19 viral replication. RP7214 has also been studied extensively across multiple inflammation models where it has demonstrated excellent anti-inflammatory activity. Further, the IND-enabling preclinical studies have shown RP7214 to be orally available, safe and tolerable with predictable dose-linear pharmacokinetics. The host-based mechanism of RP7214 could allow complementary combinations with direct acting anti-viral drugs, while the broad anti-inflammatory action could potentially mitigate the cytokine mediated inflammatory symptoms typically seen in SARS-CoV-2 & other viral infections.
Swaroop Vakkalanka, President & CEO of Rhizen Pharmaceuticals said “There is an exceptional need for oral antiviral drugs that are suitable for Covid-19 treatment across all hospital and out-patient settings. We are pleased to advance RP7214 into a Phase 1 clinical trial for the treatment of Covid-19 under a US FDA IND. RP7214 has a unique preclinical profile, high oral bioavailability, robust anti-viral potency and broad anti-inflammatory role, that we expect will translate in the clinic and support its eventual development as a potential treatment for Covid-19 ”.
About Rhizen Pharmaceuticals S.A.:
Rhizen Pharmaceuticals is an innovative, clinical-stage biopharmaceutical company focused on the discovery and development of novel onco-therapeutics. Since its establishment in 2008, Rhizen has created a diverse pipeline of proprietary drug candidates targeting several cancers and immune associated cellular pathways. Rhizen is headquartered in La-Chaux-de-Fonds, Switzerland. For additional information, please visit www.rhizen.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20201201005815/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
NIKE, Inc. Announces Planned CFO Transition23.6.2026 22:17:00 CEST | Press release
David M. Denton named incoming Chief Financial Officer NIKE, Inc. (NYSE:NKE) today announced that David M. Denton will join the company as Executive Vice President and Chief Financial Officer, effective August 17. Matthew Friend will step down as Executive Vice President and Chief Financial Officer at that time and remain with the company through September 4 to support an orderly transition. Friend will participate in the company’s fourth quarter fiscal 2026 earnings call on June 30, as planned. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260623328558/en/ David M. Denton | Incoming Executive Vice President & Chief Financial Officer, NIKE, Inc. Denton will lead Nike’s global finance organization, partnering with President and Chief Executive Officer Elliott Hill and the Senior Leadership Team to support disciplined execution, capital allocation, and long-term value creation. “Dave is a proven public-company CFO who knows h
Grid Dynamics Hosted XT26, Convening Capital Markets Technology Leaders on the Volatility of AI in Financial Services23.6.2026 22:05:00 CEST | Press release
Key Takeaways: Grid Dynamics hosted XT26, an invite-only forum focused on the volatility of AI in financial services. XT26 attendees and speakers included over 250 senior technology leaders from global financial institutions such as Bank of America, Citi, HSBC, UBS, JP Morgan, Morgan Stanley, and others. Grid Dynamics Holdings, Inc. (Nasdaq: GDYN) (“Grid Dynamics”), a premier AI transformation partner for the Fortune 1000, hosted XT26. The invite-only conference convened over 250 senior technology leaders from banking, hedge funds, and capital markets at Tower Hill, London. Now in its 10th year, the XT conference series has grown into one of financial services engineering's most respected peer forums in London, built on a single premise: pure thought leadership grounded in real-world experience, with no sales pitches, and no vendor presentations. Just practitioners who are actually doing the work. This press release features multimedia. View the full release here: https://www.businessw
Thales Secures Significant U.S. Army LOCODA Radio Order Following Rapid Development Push23.6.2026 19:42:00 CEST | Press release
The U.S. Army has selected the Thales Radio Adaptable Transport (RAT) to support the Service’s Low Cost Data Architecture (LOCODA) tactical communications transformation effort. Rapidly developed and production ready, LOCODA RAT delivers scalable, modular, multi-transport voice and data connectivity designed to support evolving operational requirements across current and future mounted platforms. Built on a commercial-off-the-shelf and non-developmental item approach, LOCODA RAT scales production, supports continuous upgrades, and reduces integration complexity and lifecycle costs. Delivering capability at mission speed, Thales subsidiary, Thales Defense & Security, Inc. (TDSI), has secured an order for up to 5,000 Low Cost Data Architecture (LOCODA) Radio Adaptable Transport (RAT) platforms. The Thales RAT solution, which was conceived, developed and field-ready less than four months, modernizes voice and data communications and integrates effortlessly into radio mounts across all cur
Epicor Prism Launches Across European Markets, Bringing Embedded, Industry-Specific AI to Manufacturers23.6.2026 17:55:00 CEST | Press release
New AI capabilities help organisations enhance operational decision-making Epicor has expanded its AI-driven ERP strategy in the UK and select European markets with the general availability of Epicor Prism, a portfolio of vertical AI agents designed specifically for the supply chain industries. Embedded directly in Epicor Kinetic, Epicor Prism gives customers conversational access to live ERP data and related documents without needing specialised analytics skills or separate AI tools. The launch reflects a broader shift in ERP from systems of record to systems of outcomes that help users interpret data, make decisions and take action in real time — a transformation Epicor calls Cognitive ERP. Responding to pressure on productivity and skills European manufacturers are under growing pressure to raise productivity, strengthen supply chain resilience and remain globally competitive despite workforce constraints and ongoing digital skills shortages. While many organisations continue to inv
Airship Appoints Laura Zwahlen as Chief Revenue Officer23.6.2026 17:00:00 CEST | Press release
Go-To-Market and Revenue Operations Veteran to Lead Global Sales and Customer Success Organizations into the Next Phase of Growth Airship, the mobile-first customer experience company, today announced the appointment of Laura Zwahlen as Chief Revenue Officer (CRO). Zwahlen will oversee all global revenue-generating activities, driving the alignment, execution, and strategy across Airship’s sales, account management, and customer success teams to accelerate the company’s market leadership and customer impact. She will report directly to CEO Brett Caine. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260623145620/en/ Laura Zwahlen, Chief Revenue Officer (CRO) of Airship Zwahlen brings more than 20 years of go-to-market and revenue leadership experience, with a proven track record of guiding technology organizations through rapid growth, strategic acquisitions, and public offerings. Previously, she served as CRO at NextRoll (th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom